Literature DB >> 20847441

Do amyloid β-associated factors co-deposit with Aβ in mouse models for Alzheimer's disease?

Nienke M Timmer1, H Bea Kuiperij, Robert M W de Waal, Marcel M Verbeek.   

Abstract

Senile plaques and cerebral amyloid angiopathy in Alzheimer's disease (AD) patients not only consist of the amyloid-β protein (Aβ), but also contain many different Aβ-associated factors, such as heparan sulfate proteoglycans, apolipoproteins, and complement factors. These factors may all influence Aβ deposition, aggregation, and clearance and therefore seem important in the development of human Aβ deposits. To study AD pathology and test new therapeutic agents, many different mouse models have been created. By transgenic expression of the amyloid-β protein precursor, frequently in combination with other transgenes, these animals develop Aβ deposits that morphologically resemble their human counterparts. Whether this resemblance also applies to the presence of Aβ-associated factors is largely unclear. In this review, the co-deposition of factors known to associate with human Aβ deposits is summarized for several different AD mouse models.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20847441     DOI: 10.3233/JAD-2010-100711

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  5 in total

1.  What does complement do in Alzheimer's disease? Old molecules with new insights.

Authors:  Yong Shen; Libang Yang; Rena Li
Journal:  Transl Neurodegener       Date:  2013-10-12       Impact factor: 8.014

2.  Limitations of the hCMEC/D3 cell line as a model for Aβ clearance by the human blood-brain barrier.

Authors:  Elisanne A L M Biemans; Lieke Jäkel; Robert M W de Waal; H Bea Kuiperij; Marcel M Verbeek
Journal:  J Neurosci Res       Date:  2016-10-11       Impact factor: 4.164

3.  CA-30, an oligosaccharide fraction derived from Liuwei Dihuang decoction, ameliorates cognitive deterioration via the intestinal microbiome in the senescence-accelerated mouse prone 8 strain.

Authors:  Jianhui Wang; Xi Lei; Zongjie Xie; Xiaorui Zhang; Xiaorui Cheng; Wenxia Zhou; Yongxiang Zhang
Journal:  Aging (Albany NY)       Date:  2019-06-03       Impact factor: 5.682

4.  A New Serum Biomarker Set to Detect Mild Cognitive Impairment and Alzheimer's Disease by Peptidome Technology.

Authors:  Koji Abe; Jingwei Shang; Xiaowen Shi; Toru Yamashita; Nozomi Hishikawa; Mami Takemoto; Ryuta Morihara; Yumiko Nakano; Yasuyuki Ohta; Kentaro Deguchi; Masaki Ikeda; Yoshio Ikeda; Koichi Okamoto; Mikio Shoji; Masamitsu Takatama; Motohisa Kojo; Takeshi Kuroda; Kenjiro Ono; Noriyuki Kimura; Etsuro Matsubara; Yosuke Osakada; Yosuke Wakutani; Yoshiki Takao; Yasuto Higashi; Kyoichi Asada; Takehito Senga; Lyang-Ja Lee; Kenji Tanaka
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

5.  Catalytically active tissue transglutaminase colocalises with Aβ pathology in Alzheimer's disease mouse models.

Authors:  Micha M M Wilhelmus; Mieke de Jager; August B Smit; Rolinka J van der Loo; Benjamin Drukarch
Journal:  Sci Rep       Date:  2016-02-03       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.